Biogen Inc. reported second quarter 2026 financial results with total revenue of $2.7 billion, a 3% year-over-year increase. GAAP diluted EPS was $0.66 and Non-GAAP diluted EPS was $3.60. The company updated its full year 2026 Non-GAAP diluted EPS guidance to $12.00–$13.00, reflecting approximately $0.85 of dilution from the Apellis acquisition completed in May 2026. Biogen expects transaction run rate synergies of at least $250 million by exiting 2027 and remains on track for accretion in 2027. The company also announced Phase 2 proof-of-concept data for BIIB091 in multiple sclerosis and exercised an option to license BIIB147 from Ionis for a $15 million fee. Biogen Inc. is a biotechnology company that develops and commercializes treatments for neurological, neurodegenerative, and rare diseases.
